Company Description: Glyscend Therapeutics is a clinical-stage biopharmaceutical company that is reshaping the treatment of metabolic disease with first-in-class oral polymeric drugs that have the potential to address significant unmet needs for patients globally, with an initial focus on obesity and type 2 diabetes. The company’s lead candidate, GLY-200, selectively targets duodenal mucosa to modulate metabolic signaling and replicate the significant clinical benefits observed after gastric bypass surgery but with a convenient oral drug. GLY-200 has recently achieved clinical proof of concept with significant reductions in body weight and blood glucose in a Phase 2a clinical study with type 2 diabetes patients. Longer term Phase 2b studies with GLY-200 in obese and type 2 diabetes patients are planned to initiate in 2024. The company is currently fundraising to support the advancement of GLY-200, following a $20.5M Series A round in 2020 led by Sante´ Ventures and Brandon Capital Partners.